Drug Profile
Research programme: cancer therapeutics - Janssen Biotech/University of Texas M.D Anderson Cancer Center
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Janssen Biotech; University of Texas M. D. Anderson Cancer Center
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Cancer in USA
- 08 Jan 2014 Early research in Cancer in USA (unspecified route)